{"doi":"10.2967/jnumed.113.126342","title":"<sup>18</sup>F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO","abstract":null,"journal":"Journal of Nuclear Medicine","year":2013,"id":596412,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1527485,"name":"Laura M. Kenny","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"<sup>18</sup>F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO","abstract":"Since its original characterization in breast cancer nearly 30 y ago, the human epidermal growth factor receptor 2 (HER2) has become a key target for cancer therapeutics ([1][1],[2][2]). HER2 is overexpressed in approximately 20% of breast cancers and is an adverse prognostic factor as it promotes","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"24071512","pmcid":null,"openalex_id":"https://openalex.org/W2304210427","authors":[],"funders":[{"funder_name":"National Institute for Health Research (NIHR)","grant_id":"NIHR/CS/009/009","title":null}],"total_grants":1,"fwci":0.2392,"citation_percentile":0.64237188,"influential_citations":0,"citation_trend":[{"year":2014,"count":1},{"year":2019,"count":1},{"year":2025,"count":1}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"http://jnm.snmjournals.org/content/54/11/1855.full.pdf","host_type":"journal"},{"url":"http://jnm.snmjournals.org/content/54/11/1855.full.pdf","host_type":"publisher"},{"url":"https://syndication.highwire.org/content/doi/10.2967/jnumed.113.126342","host_type":"publisher"},{"url":"https://doi.org/10.2967/jnumed.113.126342","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/24071512","host_type":"repository"}],"fields_of_study":["Medical Imaging Techniques and Applications","HER2/EGFR in Cancer Research","Radiomics and Machine Learning in Medical Imaging","Breast Neoplasms","Female","Fluorodeoxyglucose F18","Humans","Neoadjuvant Therapy","Positron-Emission Tomography","Erb-b2 Receptor Tyrosine Kinases","Tomography, X-Ray Computed"],"mesh_terms":["Breast Neoplasms","Female","Humans","Tomography, X-Ray Computed","Erb-b2 Receptor Tyrosine Kinases","Receptor, ErbB-2","Fluorodeoxyglucose F18","Neoadjuvant Therapy","Positron-Emission Tomography"],"keywords":["Lapatinib","Trastuzumab","Breast cancer","Medicine","Human Epidermal Growth Factor Receptor 2","Oncology","Cancer","Internal medicine","Metastatic breast cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T10:11:12.310427Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}